PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: September 01, 2016 Report Code: GDHC125PIDR-ST

Select Item

Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels of inattention, impulsivity, and hyperactivity, either alone or in combination that have a significant social impact through disruptions at school, work, home, and in relationships. The majority of children with the disorder will continue to experience symptoms into adolescence. 30-50% of children diagnosed with ADHD continue to have problems into adulthood resulting in 2-5% of adults having ADHD.

Growth is expected in the global ADHD marketplace, despite the market being widely genericized. This will be driven largely by the anticipated launch of assets from the heavily populated ADHD pipeline, as these products offer clinical advantages that will drive strong uptake. Furthermore, the number of drug-treated patients will increase over the forecast period, driven by increased treatment rates throughout the 7MM, particularly in the adult age group.

Scope

Overview of ADHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized ADHD market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.

Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the ADHD therapeutics market.

Pipeline analysis: focus on 13 late-stage pipeline ADHD drugs discussing emerging trends as well as an overview of earlier phase drugs.

Analysis of the current and future market competition in the global ADHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The ADHD market has been dominated by stimulant therapy, with only three approved non-stimulant drugs approved that cannot compete with stimulant drugs in terms of efficacy. Due to lack of evidence for long-term safe use of stimulants, non-stimulants are becoming increasingly popular in the 7MM. Both stimulant and non-stimulant therapies are anticipated to reach the market within the forecast period. How will these change the market overall during the forecast period? Will stimulants maintain market dominance in 2024?

The current late stage ADHD pipeline is heavily populated, drugs designed to satisfy what GlobalData has identified as unmet needs. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this crowded market?

ADHD is becoming increasingly recognized, particularly n the adult population, leading to increase number in treated patients across the 7MM. How will these changes impact the growth of the future market?

Alcobra
Amarantus
Curemark
Eli Lilly*
Highland Therapeutics*
Janssen*
Mallinckrodt
Medice
Neos Therapeutics
Neurovance
Nextwave Pharmaceuticals
Novartis*
Noven Pharmaceuticals
Pfizer+
Recordati
Rhodes Pharmaceuticals
Shionogi
Shire*
Sunovion Pharmaceuticals
Supernus Pharmaceuticals
Tris Pharma+
UCB
*Have received company profile
+Have received joint profile

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Classification

3.2.1Predominantly Inattentive Type

3.2.2Predominantly Hyperactive-Impulsive Type

3.2.3Combined Type

3.2.4Other Specified ADHD Type

3.2.5Unspecified Type

3.2.6Severity

3.3Symptoms

3.4Prognosis

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1US

4.3.25EU

4.3.3Japan

4.4Forecast Methodology

4.4.1Sources Used Tables

4.4.2Forecast assumptions and methods

4.4.3Sources Not Used

4.5Epidemiological Forecast for ADHD (2014–2024)

4.5.1Diagnosed Prevalent Cases of ADHD

4.5.2Age-Specific Diagnosed Prevalent Cases of ADHD

4.5.3Sex-Specific Diagnosed Prevalent Cases of ADHD

4.5.4Age-Standardized Prevalence of ADHD

4.5.5Diagnosed Prevalent Cases of ADHD by Subtype

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Disease Management

5.1Diagnosis and Treatment Overview

5.1.1Diagnosis

5.1.2Treatment Guidelines and Leading Prescribed Drugs

5.1.3Clinical Practice

5.2US

5.35EU

5.4Japan

6Competitive Assessment

6.1Overview

6.2Product Profiles – Amphetamine (Stimulant)

6.2.1Dextroamphetamine

6.2.2Desoxyn (methamphetamine)

6.2.3Adderall XR (Mixed amphetamine Salts)

6.2.4Vyvanse (lisdexamphetamine dimesylate)

6.2.5Dyanavel XR (Liquid Amphetamine XR)

6.2.6Adzenys XR-ODT (Amphetamine Extended Release-Orally Disintegrating Tablet)

6.3Product Profiles – Methylphenidate (Stimulant)

6.3.1Ritalin LA

6.3.2Concerta

6.3.3Medikinet XL

6.3.4Metadate CD

6.3.5Methylin

6.3.6Focalin

6.3.7Daytrana

6.3.8Quillivant XR/Quillichew

6.3.9Aptensio XR

6.4Product Profiles – Non-stimulants

6.4.1Strattera (Atomoxetine Hydrochloride)

6.4.2Intuniv (Guanfacine Hydrochloride)

6.4.3Kapvay (Clonidine)

6.4.4Other Therapeutic Classes

7Unmet Need and Opportunity Analysis

7.1Overview

7.2More Effective, Longer-Lasting, and/or Non-stimulant Treatment Options

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Clinically Relevant, Head-to-Head Comparisons

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Improved Diagnostic Tests

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Education and Recognition of ADHD

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

7.6Discontinuation and Long-Term Safety of Stimulants

7.6.1Unmet Need

7.6.2Gap Analysis

7.6.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Clinical Trial Mapping

8.2.1Clinical Trials by Class

8.3Overview of Promising Drugs in Clinical Development

8.4Promising Amphetamine Drugs in Clinical Development

8.4.1NT-0201 (Liquid Amphetamine XR)

8.4.2SHP-465 (Triple-Bead Mixed Amphetamine Salts)

8.4.3HLD-100 (Dextroamphetamine MR)

8.4.4Amphetamine Transdermal System (Dextroamphetamine)

8.5Promising Methylphenidate Drugs in Clinical Development

8.5.1Cotempla XR-ODT (Extended-Release ODT Methylphenidate)

8.5.2Benjorna (Methylphenidate Hydrochloride MR)

8.6Promising Non-stimulant Drugs in Clinical Development

8.6.1SEP-225289 (Dasotraline)

8.6.2Centanafadine SR

8.6.3SPN-810 (Molindone Hydrochloride ER)

8.6.4SPN-812 (Viloxazine Hydrochloride)

8.6.5Metadoxine ER

8.6.6Eltoprazine

8.6.7CM-4612

8.7Other Drugs in Development

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Shire

9.3.2Novartis

9.3.3Janssen

9.3.4Eli Lilly

9.3.5Pfizer/Tris Pharma

9.3.6Highland Therapeutics

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.35EU

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Japan

10.4.1Forecast

10.4.2Key Events

10.4.3Driver and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed ADHD Patients

11.4.2Percent Drug-Treated Patients

11.4.3Launch and Patent Expiry Dates

11.4.4General Pricing Assumptions

11.4.5Individual Drug Assumptions

11.4.6Generic Erosion

11.4.7Pricing of Pipeline Agents

11.5Primary Research – KOLs Interviewed for This Report

11.6Primary Research – Prescriber Survey

11.7About the Authors

11.7.1Analyst

11.7.2Therapy Area Director

11.7.3Epidemiologists

11.7.4Managing Epidemiologists

11.7.5Global Director of Therapy Analysis and Epidemiology

11.8About GlobalData

11.9Contact Us

11.10Disclaimer

Table

Table 1: Classification of ADHD According to the DSM-V and ICD-10-CM

Table 2: Symptoms of ADHD

Table 3: Prognosis and Risks Associated with ADHD

Table 4: Risk Factors and Comorbidities for ADHD

Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD

Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 3?17 Years

Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages =18 Years

Table 8: 7MM, Sources Not Used in Epidemiological Analysis of ADHD

Table 9: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages =3 Years, Select Years, 2014–2024

Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, N (Row%), 2014

Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages =3 Years, N (Row %), 2014

Table 12: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3–17 Years, Children and Adolescents, N (Row %), 2014

Table 13: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages =18 Years, Adults, N (Row %), 2014

Table 14: Rating Scales Used for ADHD

Table 15: Treatment Guidelines for Disease ADHD

Table 16: Most Prescribed Drugs for ADHD by Class in the Global Markets, 2014

Table 17: Country Profile – US

Table 18: Country Profile – 5EU

Table 19: Country Profile – Japan

Table 20: Leading Treatments for ADHD, 2015

Table 21: Product Profile — Dextroamphetamine

Table 22: Dextroamphetamine SWOT Analysis, 2015

Table 23: Global Sales Forecasts ($m) for Dextroamphetamine, 2014–2024

Table 24: Product Profile – Desoxyn

Table 25: Desoxyn SWOT Analysis, 2015

Table 26: Global Sales Forecasts ($m) for Desoxyn, 2014–2024

Table 27: Product Profile – Adderall XR

Table 28: Adderall XR SWOT Analysis, 2015

Table 29: Global Sales Forecasts ($m) for Adderall XR, 2014–2024

Table 30: Product Profile – Vyvanse

Table 31: Vyvanse SWOT Analysis, 2015

Table 32: Global Sales Forecasts ($m) for Vyvanse, 2014–2024

Table 33: Product Profile – Dyanavel XR

Table 34: Dyanavel SWOT Analysis, 2015

Table 35: Global Sales Forecasts ($m) for Dyanavel XR, 2014–2024

Table 36: Product Profile – Adzenys XR-ODT

Table 37: Adzenys XR-ODT SWOT Analysis, 2015

Table 38: Global Sales Forecasts ($m) for Adzenys XR-ODT, 2014–2024

Table 39: Product Profile – Ritalin LA

Table 40: Ritalin LA SWOT Analysis, 2015

Table 41: Global Sales Forecasts ($m) for Ritalin LA, 2014–2024

Table 42: Product Profile – Concerta

Table 43: Concerta SWOT Analysis, 2015

Table 44: Global Sales Forecasts ($m) for Concerta, 2014–2024

Table 45: Product Profile – Medikinet XL

Table 46: Medikinet SWOT Analysis, 2015

Table 47: Global Sales Forecasts ($m) for Medikinet XL, 2014–2024

Table 48: Product Profile – Metadate CD

Table 49: Incidence of TEAEs in a Pool of 3–4 Week Clinical Trials – Metadate CD

Table 50: Metadate CD SWOT Analysis, 2015

Table 51: Global Sales Forecasts ($m) for Metadate CD, 2014–2024

Table 52: Product Profile – Methylin

Table 53: Methylin SWOT Analysis, 2015

Table 54: Global Sales Forecasts ($m) for Methylin, 2014–2024

Table 55: Product Profile – Focalin

Table 56: TEAEs – Focalin

Table 57: TEAEs – Focalin XR

Table 58: Focalin SWOT Analysis, 2015

Table 59: Global Sales Forecasts ($m) for Focalin and Focalin XR, 2014–2024

Table 60: Product Profile – Daytrana

Table 61: Daytrana SWOT Analysis, 2015

Table 62: Global Sales Forecasts ($m) for Daytrana, 2014–2024

Table 63: Product Profile – Quillivant XR

Table 64: Quillichew Primary Efficacy Result

Table 65: Quillivant XR SWOT Analysis, 2015

Table 66: Global Sales Forecasts ($m) for Quillivant XR/Quillichew, 2014–2024

Table 67: Product Profile – Aptensio XR

Table 68: Summary of the Parallel Group Study – Aptensio XR

Table 69: Aptensio XR SWOT Analysis, 2015

Table 70: Global Sales Forecasts ($m) for Aptensio XR, 2014–2024

Table 71: Product Profile – Strattera

Table 72: Acute and Maintenance Efficacy Studies – Strattera

Table 73: Common TEAEs reported in acute trials in children and adolescents – Strattera

Table 74: Common TEAEs reported in acute trials in adults – Strattera

Table 75: Strattera SWOT Analysis, 2015

Table 76: Global Sales Forecasts ($m) for Strattera, 2014–2024

Table 77: Product Profile – Intuniv

Table 78: Fixed Dose Studies– Intuniv

Table 79: Intuniv SWOT Analysis, 2015

Table 80: Global Sales Forecasts ($m) for Intuniv, 2014–2024

Table 81: Product Profile – Kapvay

Table 82: Kapvay SWOT Analysis, 2015

Table 83: Global Sales Forecasts ($m) for Kapvay, 2014–2024

Table 84: Unmet Need and Opportunity in ADHD

Table 85: Drugs in Development, 2016

Table 86: Comparison of Therapeutic Classes in Development for ADHD, 2014–2024

Table 87: Product Profile – Liquid Amphetamine XR, NT-0201

Table 88: NT-0201 SWOT Analysis, 2015

Table 89: Global Sales Forecasts ($m) for NT-0201, 2014–2024

Table 90: Product Profile – Triple-Bead Mixed Amphetamine Salts (SHP-465)

Table 91: SHP-465 SWOT Analysis, 2015

Table 92: Global Sales Forecasts ($m) for SHP-465, 2014–2024

Table 93: Product Profile – HLD-100

Table 94: HLD-100 SWOT Analysis, 2015

Table 95: Global Sales Forecasts ($m) for HLD-100, 2014–2024

Table 96: Product Profile – Dextroamphetamine Transdermal Patch

Table 97: Dextroamphetamine Transdermal Patch SWOT Analysis, 2015

Table 98: Global Sales Forecasts ($m) for ATS, 2014–2024

Table 99: Product Profile – Cotempla XR-ODT

Table 100: Cotempla XR-ODT SWOT Analysis, 2015

Table 101: Global Sales Forecasts ($m) for Cotempla XR-ODT, 2014–2024

Table 102: Product Profile – Benjorna

Table 103: Benjorna SWOT Analysis, 2015

Table 104: Global Sales Forecasts ($m) for Benjorna, 2014–2024

Table 105: Product Profile – Dasotraline

Table 106: Dasotraline SWOT Analysis, 2015

Table 107: Global Sales Forecasts ($m) for dasotraline, 2014–2024

Table 108: Product Profile – Centanafadine SR

Table 109: Centanafadine SR SWOT Analysis, 2015

Table 110: Global Sales Forecasts ($m) for centanafadine SR, 2014–2024

Table 111: Product Profile – SPN-810

Table 112: SPN-810 SWOT Analysis, 2015

Table 113: Global Sales Forecasts ($m) for SPN-810, 2014–2024

Table 114: Product Profile – Viloxazine

Table 115: Viloxazine SWOT Analysis, 2015

Table 116: Global Sales Forecasts ($m) for Pipeline Viloxazine, 2014–2024

Table 117: Product Profile – Metadoxine ER

Table 118: Metadoxine ER SWOT Analysis, 2015

Table 119: Global Sales Forecasts ($m) for Metadoxine ER, 2014–2024

Table 120: Product Profile – Eltoprazine

Table 121: Eltoprazine SWOT Analysis, 2015

Table 122: Global Sales Forecasts ($m) for Eltoprazine, 2014–2024

Table 123: Product Profile – CM-4612

Table 124: CM-4612 SWOT Analysis, 2015

Table 125: Global Sales Forecasts ($m) for CM-4612, 2014–2024

Table 126: Drugs in Development, 2016

Table 127: Key Companies in the ADHD Market in the 7MM, 2014

Table 128: Shire’s ADHD Portfolio Assessment, 2015

Table 129: Novartis’ ADHD Portfolio Assessment, 2015

Table 130: Janssen’s ADHD Portfolio Assessment, 2015

Table 131: Eli Lilly’s ADHD Portfolio Assessment, 2015

Table 132: Pfizer/Tris Pharma’s ADHD Portfolio Assessment, 2015

Table 133: Highland Therapeutics’ ADHD Portfolio Assessment, 2016

Table 134: Global Sales Forecasts ($m) for ADHD, 2014–2024

Table 135: ADHD Market – Global Drivers and Barriers, 2014?2024

Table 136: Sales Forecasts ($m) for ADHD in the US, 2014–2024

Table 137: Key Events Impacting Sales for ADHD in the US, 2014–2024

Table 138: ADHD Market – Drivers and Barriers in the US, 2014?2024

Table 139: Sales Forecasts ($m) for ADHD in the 5EU, 2014–2024

Table 140: Key Events Impacting Sales for ADHD in the 5EU, 2014–2024

Table 141: ADHD Market – Drivers and Barriers in the 5EU, 2014?2024

Table 142: Sales Forecasts ($m) for ADHD in Japan, 2014–2024

Table 143: Key Events Impacting Sales for ADHD in Japan, 2014–2024

Table 144: ADHD Market – Drivers and Barriers in Japan, 2014?2024

Table 145: Key ADHD Launch Dates

Table 146: Key ADHD Patent Expiries

Table 147: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country, 2016

Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages =3 Years, Selected Years, 2014–2024

Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, 2014

Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages =3 Years, 2014

Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of ADHD, Ages =3 Years, 2014

Figure 5: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3–17 Years, Children and Adolescents, N, 2014

Figure 6: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages =18 Years, Adults, N, 2014

Figure 7: Treatment Algorithm for ADHD in the 7MM

Figure 8: ADHD Therapeutics – Class of Therapy, 2016

Figure 9: ADHD – Phase II–III Pipeline, 2016

Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in ADHD, 2014–2024

Figure 11: Clinical and Commercial Positioning of NT-0201

Figure 12: Clinical and Commercial Positioning of SHP-465

Figure 13: Clinical and Commercial Positioning of HLD-100

Figure 14: Clinical and Commercial Positioning of ATS

Figure 15: Clinical and Commercial Positioning of Cotempla XR-ODT

Figure 16: Clinical and Commercial Positioning of Benjorna

Figure 17: Clinical and Commercial Positioning of Dasotraline

Figure 18: Clinical and Commercial Positioning of Centanafadine SR

Figure 19: Clinical and Commercial Positioning of SPN-810

Figure 20: Clinical and Commercial Positioning of Viloxazine

Figure 21: Clinical and Commercial Positioning of Metadoxine ER

Figure 22: Clinical and Commercial Positioning of Eltoprazine

Figure 23: Clinical and Commercial Positioning of CM-4612

Figure 24: Global Sales of Branded Products for ADHD by Company, 2014–2024

Figure 25: Company Portfolio Gap Analysis in ADHD, 2014–2024

Figure 26: Shire SWOT Analysis in ADHD, 2014–2024

Figure 27: Novartis SWOT Analysis in ADHD, 2014–2024

Figure 28: Janssen SWOT in ADHD, 2014–2024

Figure 29: Eli Lilly SWOT Analysis in ADHD, 2014–2024

Figure 30: Pfizer/Tris Pharma SWOT Analysis in ADHD, 2014–2024

Figure 31: Highland Therapeutics SWOT Analysis in ADHD, 2014–2024

Figure 32: Global Sales for ADHD by Country, 2014 and 2024

Figure 33: Global Sales for ADHD by Drug Class, 2014 and 2024

Figure 34: Sales for ADHD by Drug Class in the US, 2014 and 2024

Figure 35: Sales for ADHD by Drug Class in the 5EU, 2014 and 2024

Figure 36: Sales for ADHD by Drug Class in Japan, 2014 and 2024

Frequently asked questions

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024 in real time.

  • Access a live PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more